
Lene Kongsgaard Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8178372/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A systematic review of healthâ€related quality of life in longitudinal studies of myeloma patients. European Journal of Haematology, 2017, 99, 3-17.	2.2	54
2	Implications of response shift for micro-, meso-, and macro-level healthcare decision-making using results of patient-reported outcome measures. Quality of Life Research, 2021, 30, 3343-3357.	3.1	38
3	Strategies to improve patient-reported outcome completion rates in longitudinal studies. Quality of Life Research, 2020, 29, 335-346.	3.1	27
4	Clinical presentation and mortality in hospitalized patients aged 80+ years with COVID-19–A retrospective cohort study. Archives of Gerontology and Geriatrics, 2021, 94, 104335.	3.0	24
5	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica, 2020, 105, 1650-1659.	3.5	19
6	Methodological aspects of healthâ€related quality of life measurement and analysis in patients with multiple myeloma. British Journal of Haematology, 2019, 185, 11-24.	2.5	13
7	Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a populationâ€based study from the Danish national multiple myeloma registry. British lournal of Haematology, 2021, 193, 119-124.	2.5	12
8	A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Experimental Hematology and Oncology, 2018, 7, 18.	5.0	9
9	Clarithromycin added to bortezomibâ€cyclophosphamideâ€dexamethasone impairs healthâ€related quality of life in multiple myeloma patients. European Journal of Haematology, 2019, 102, 70-78.	2.2	8
10	Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program. Annals of Hematology, 2021, 100, 2311-2323.	1.8	7
11	Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients. Blood, 2020, 136, 20-20.	1.4	4
12	The impact of changed treatment patterns in multiple myeloma on healthâ€care utilisation and costs, myeloma complications, and survival: A populationâ€based comparison between two time periods in Denmark. European Journal of Haematology, 2021, 107, 63-73.	2.2	3
13	Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry. Blood, 2019, 134, 1849-1849.	1.4	2
14	Health-Related Quality of Life (HRQoL) Measurements in Multiple Myeloma Patients Obtained By EORTC QLQ-C30; A Critical Review of Interpreting HRQoL Data in Longitudinal Studies. Blood, 2016, 128, 540-540.	1.4	1
15	Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. Health and Quality of Life Outcomes, 2021, 19, 251.	2.4	1
16	A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e279-e280.	0.4	0
17	Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. Covid, 2021, 1, 303-314.	1.5	0
18	The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey. Blood, 2021, 138, 1638-1638.	1.4	0